Xoma Discontinues All Gevokizumab Development Activities

Biopharmaceutical company Xoma has ceased all development activities related to the monoclonal antibody gevokizumab.

The therapy was in Phase 3 testing for the treatment of pyoderma gangrenosum, but data from the 25-patient study did not demonstrate efficacy to warrant continuation, the company said. Xoma had been jointly developing the candidate with Les Laboratories Servier for a number of indications, none of which has panned out.